Serum sickness following rituximab therapy in a patient with pemphigus vulgaris: A case report

Khatib, Mohamad; Allafi, Solaiman; Nashwan, Abdulqadir J.

doi:10.1002/ccr3.3642

Cited by 2 publications

(4 citation statements)

References 24 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…There have been 4 other case reports representing RISS sickness in PV patients. 17,18,21,22 The mean age of RISS occurrence in PV cases was 37 ± 12.21 years. All described cases had similar presentations.…”

Section: Discussionmentioning

confidence: 98%

“…Table 2 shows the clinical symptoms of the RISS patients. 17 , 18 , 21 , 22 Polyarthralgia, fever, and skin involvement are the most common symptoms. Less frequent symptoms included lethargy, conjunctivitis, and digestive disorders.…”

Section: Discussionmentioning

confidence: 99%

“…Table 1 presents the details and comparison of RISS in PV that were reported previously, in addition to the current study. There have been 4 other case reports representing RISS sickness in PV patients 17,18,21,22 . The mean age of RISS occurrence in PV cases was 37 ± 12.21 years.…”

Section: Discussionmentioning

confidence: 99%

“…Table 2 shows the clinical symptoms of the RISS patients 17,18,21,22 . Polyarthralgia, fever, and skin involvement are the most common symptoms.…”

Section: Discussionmentioning

confidence: 99%

See 3 more Smart Citations

Rituximab‐induced serum sickness in immunobullous disorders: A case series

Gheisari,

Safari Giv,

Pourgholi

et al. 2024

Clinical Case Reports

View full text Add to dashboard Cite

Key Clinical MessageRituximab‐induced serum sickness (RISS) is a rare complication of Rituximab (RTX) in immunobullous disorders. Clinicians should be aware of the occurrence of serum sickness symptoms during RTX administration, and prompt initiation of corticosteroid therapy is crucial in these patients. Additionally, RISS may occur with subsequent RTX doses and patients should be counseled accordingly.AbstractRituximab (RTX) is a chimeric monoclonal anti‐CD20 antibody which has gained approval for the treatment of various autoimmune and lymphoproliferative disorders. While RTX‐induced minor reactions, including immediate infusion‐related reactions, are common, serum sickness is rare. Limited data exist regarding rituximab‐induced serum sickness (RISS) in pemphigus vulgaris (PV) and mucous membrane pemphigoid (MMP). We report two cases of RISS following RTX administration in PV and MMP patients. Both patients presented with typical symptoms of serum sickness after RTX infusion, necessitating drug cessation and corticosteroid therapy for resolution. RISS represents a rare complication of RTX therapy. Clinicians should maintain awareness of serum sickness presentations during and post‐RTX administration.

show abstract

Section: Discussionmentioning

confidence: 98%

Section: Discussionmentioning

confidence: 99%

Section: Discussionmentioning

confidence: 99%

“…Table 2 shows the clinical symptoms of the RISS patients 17,18,21,22 . Polyarthralgia, fever, and skin involvement are the most common symptoms.…”

Section: Discussionmentioning

confidence: 99%

See 2 more Smart Citations

Rituximab‐induced serum sickness in immunobullous disorders: A case series

Gheisari,

Safari Giv,

Pourgholi

et al. 2024

Clinical Case Reports

View full text Add to dashboard Cite

show abstract

Multiple drugs

2021

Reactions Weekly

View full text Add to dashboard Cite

Multiple drugsLack of drug effect and serum sickness: case report A 33-year-old man exhibited a lack of drug effect during treatment with immune-globulin, azathioprine and prednisolone for pemphigus vulgaris. Additionally, he developed serum sickness during treatment with rituximab for refractory pemphigus vulgaris [not all routes stated].The man was hospitalised with fever, malaise, arthralgia and myalgia for one day. Two weeks prior the admission, he started receiving IV rituximab 1000mg 2 times a week for severe refractory pemphigus vulgaris. Previously, he had received treatment with IV immune-globulin [IVIg] 2 g/kg every cycle, azathioprine 2.5 mg/kg and prednisolone 2 mg/kg/day for pemphigus vulgaris for two years. However, the pemphigus vulgaris became refractory. Therefore, rituximab was added to his treatment. Examinations showed fever, haemodynamic instability with sinus tachycardia, generalised body rash and pain, and mild tachypnoea. He had severe pain on movement. Initially, he started receiving piperacillin/tazobactam for suspected sepsis; however, it was stopped after the admission. His laboratory tests showed an increase in leukocyte, erythrocyte counts, CRP, uric acid and creatinine. Other lab tests were nonsignificant. Therefore, rituximab-induced serum sickness was diagnosed.Therefore, the man started receiving methylprednisolone, paracetamol, morphine and fentanyl patches. Following 2 days, his condition resolved. After 4 days, he was discharged from the hospital.

show abstract

Serum sickness following rituximab therapy in a patient with pemphigus vulgaris: A case report

Cited by 2 publications

References 24 publications

Rituximab‐induced serum sickness in immunobullous disorders: A case series

Rituximab‐induced serum sickness in immunobullous disorders: A case series

Multiple drugs

Contact Info

Product

Resources

About